A satellite symposium held in conjunction with the 17th European Congress: Perspectives in Lung Cancer

CURRENT INSIGHTS AND PERSPECTIVES IN NSCLC TREATMENT

Saturday 5th March 2016 12:05–13:35

Congress Hall I & II, Hilton Prague Prague, Czech Republic

chairpersonPieter E. Postmus Clatterbridge Cancer Centre, Liverpool, United Kingdom

speakersMaximilian Hochmair Otto Wagner Spital, Vienna, Austria

Filippo De Marinis European Institute of Oncology, Milan, Italy

David Heigener LungenClinic Grosshansdorf, Grosshansdorf, Germany

Supported by Boehringer Ingelheim

NIN_320_45_PILC_Congress_Screen/Print Agenda_fa1.indd 1 26/02/2016 15:42

Agenda

Copyright ©2016 Boehringer Ingelheim International GmbH. All rights reserved. Procedure ID: 4871 – February 2016. Supported by Boehringer Ingelheim

12:05–12:10 Welcome and introductions Pieter E. Postmus

12:10–13:10 Treatment decisions in EGFR mutation-positive NSCLC: Key elements in first-line treatment choice

• Efficacy Maximilian Hochmair

• Tolerability Filippo De Marinis

• Mutation type Filippo De Marinis

• Evaluating the evidence – panel discussion All

13:10–13:30 Targeting angiogenesis in NSCLC David Heigener

13:30–13:35 Final questions and meeting close Pieter E. Postmus

NIN_320_45_PILC_Congress_Screen/Print Agenda_fa1.indd 2 26/02/2016 15:42